Clinical trial NCT01708304: Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)
Official title: From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alzheimer's Disease
Dementia
Memory Impairment
Cognitive Impairment
Keywords: Dementia
Alzheimer's Disease
Exercise
Caregiver
Behavior modification
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2012-10-16
Enrollment: 510
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease). RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. This study asks two questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. This study is being conducted in Washington and Oregon states.


Eligibility criteria: Inclusion Criteria:

Care Recipients must

* Have a diagnosis of dementia
* Be 65 years of age or older
* Currently exercise no more than 150 minutes a week and not regularly participate in a formal exercise program.

Caregivers must

* Live in the community
* Provide care to the care recipient with dementia

Exclusion Criteria:

Either Care-recipient or Caregiver must not

* Plan to move to a long-term residential care setting within 6 months of enrollment.
* Plan to move from the study geographic area within 4 months of enrollment.
* Have a known terminal illness (with death anticipated within the next 12 months)
* Have had a hospitalization for a psychiatric disorder in the 12 months prior to baseline
* Be actively suicidal, hallucinating, or delusional
* Be blind, deaf, or not ambulatory

Primary outcomes:
measure: Minutes of exercise per week
timeFrame: Change from baseline in number of minutes of exercise each week during treatment phase of study, weeks 7-12
measure: Restricted Activity Days
timeFrame: Baseline
measure: Restricted Activity Days
timeFrame: Change from Baseline to Pre-Treatment (6 weeks)
measure: Restricted Activity Days
timeFrame: Change from Baseline to Post- Treatment 1 (13 weeks)
measure: Restricted Activity Days
timeFrame: Change from Baseline to Post-Treatment 2 (30 weeks)
measure: Restricted Days of Activity
timeFrame: Change from Baseline to 13 Month Follow-Up
measure: Independence/Residential Status
timeFrame: Change from Baseline to 13 Month Follow-Up
Secondary outcomes:
measure: Revised Memory and Behavior Problem Checklist (RMBPC)
timeFrame: Baseline
measure: Revised Memory and Behavior Problem Checklist (RMBPC)
timeFrame: Change from Baseline to Pre-Treatment (6 weeks)
measure: Revised Memory and Behavior Problem Checklist (RMBPC)
timeFrame: Change from Baseline to Post-Treatment 1 (13 weeks)
measure: Revised Memory and Behavior Problem Checklist (RMBPC)
timeFrame: Change from Baseline to Post-Treatment 2 (30 weeks)
measure: Revised Memory and Behavior Problem Checklist (RMBPC)
timeFrame: Change from Baseline to 13 Month Follow-Up
measure: Quality of Life-AD
timeFrame: Baseline
measure: Quality of Life-AD
timeFrame: Change from Baseline to Pre-Treatment (6 weeks)
measure: Quality of Life-AD
timeFrame: Change from Baseline to Post-Treatment 1 (13 weeks)
measure: Quality of Life-AD
timeFrame: Change from Baseline to Post-Treatment 2 (30 weeks)
measure: Quality of Life-AD
timeFrame: Change from Baseline to 13 Month Follow-Up
measure: CES-D
timeFrame: Baseline
measure: CES-D
timeFrame: Change from Baseline to Pre-Treatment (6 weeks)
measure: CES-D
timeFrame: Change from Baseline to Post-Treatment 1 (13 weeks)
measure: CES-D
timeFrame: Change from Baseline to Post-Treatment 2 (30 weeks)
measure: CES-D
timeFrame: Change from Baseline to 13 Month Follow-Up
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington
state: Washington
Study officials:
affiliation: University of Washington
name: Linda Teri, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Teri L, Logsdon RG, McCurry SM, Pike KC, McGough EL. Translating an Evidence-based Multicomponent Intervention for Older Adults With Dementia and Caregivers. Gerontologist. 2020 Apr 2;60(3):548-557. doi: 10.1093/geront/gny122.